Table 1.
Average incubation times and survival percentages of tga20 mice inoculated intracranially with serially diluted or treated RML scrapie brain homogenate
| Group | Dilution or treatment | Mean incubation time in days ± SD (% survival) |
|---|---|---|
| |
RML titration series* |
|
| |
100 |
66 ± 3.4 (0%) |
| |
10-1 |
74 ± 3.3 (0%) |
| |
10-2 |
83 ± 6.1 (0%) |
| |
10-3 |
128 ± 29.1 (22%) |
| |
10-4 |
184 ± 39.6 (78%) |
| |
10-5 through 10-12 |
N/A (100%) – study termination |
| |
Treated RML |
|
| |
SPC-PL* |
67 ± 2.6 (0%) |
| |
SPC-PH* |
70 ± 6.0 (0%) |
| |
SPC-PL + SDS* |
93 ± 9.7 (0%) |
| |
SPC-PH + SDS* |
93 ± 7.6 (0%) |
| 1 |
SPC-PL ∏ PK |
107 ± 39.0 (11%) |
| 2 |
SPC-PH ∏ PK |
98 ± 16.8 (0%) |
| 3 |
SPC-PL + SDS ∏ PK |
431 ± 72.4 (73%) |
| 4 |
SPC-PH + SDS ∏ PK |
108^ (88%) |
| 5 |
SDS control |
85 ± 12.3 (0%) |
| 6 |
PK control |
62 ± 5.2 (0%) |
| 7 | SDS ∏ PK control | 86 ± 7.1 (0%) |
*Smith et al.[29]; ^only 1 mouse in this group was euthanized due to clinical scrapie.
SD standard deviation.